Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
J Acquir Immune Defic Syndr ; 82(2): 220-224, 2019 10 01.
Article in English | MEDLINE | ID: mdl-31513076

ABSTRACT

BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is an often fatal disease caused by JC virus (JCV) in severely immunocompromised patients, including HIV patients. Development of therapeutics to prevent or treat PML is an urgent medical need. While JCV-specific T cells are crucial to control JCV and recover from PML, the role played by antibodies remains unclear. Anti-JCV antibodies, including potent neutralizing antibodies, can be detected in most infected adults, yet in PML patients, JCV seems to escape from neutralization. Whether antibodies can contribute to JCV control by eliciting Fc-mediated effector functions activity has not been evaluated. METHODS: We measured the capacity of plasma anti-JCV VP1 antibodies to recruit Fc receptor (FcR)-bearing effector cell functions in 28 HIV patients, comparing subjects without PML with PML survivors (PML S) who were alive 1 year after disease onset or PML progressors (PML P) who succumbed within the first year. Antibody titers against JCV VP1 and HIV gp140 trimer were determined by end-point titer dilution ELISA. FcR-mediated natural killer cell degranulation and IFN-γ production were measured as surrogate for in vitro antibody-dependent cellular cytotoxicity (ADCC). RESULTS: PML S had higher JCV antibody titers than PML P and patients without PML. However, anti-JCV antibodies had a higher ability to functionally engage FcR in PML P than PML S. Antibody titers and ADCC activity did not vary over time in PML S. Anti-HIV antibody titers and ADCC activity were similar among groups. CONCLUSIONS: The ability of anti-JCV antibodies to stimulate FcR-bearing effector cell activity might contribute to the outcome of PML. Further studies are warranted to define Fc-mediated functions of anti-JCV antibodies and evaluate whether ADCC can contain JCV replication.


Subject(s)
Antibodies, Viral/immunology , Antibody-Dependent Cell Cytotoxicity/immunology , HIV Infections/immunology , JC Virus/immunology , Leukoencephalopathy, Progressive Multifocal/immunology , Adult , Antibodies, Viral/blood , Capsid Proteins/immunology , Female , Humans , Male , Middle Aged , env Gene Products, Human Immunodeficiency Virus/immunology
3.
PLoS One ; 12(5): e0177339, 2017.
Article in English | MEDLINE | ID: mdl-28562595

ABSTRACT

BK polyomavirus (BKPyV) reactivation in kidney transplant recipients can lead to allograft damage and loss. The elements of the adaptive immune system that are permissive of reactivation and responsible for viral control remain incompletely described. We performed a prospective study evaluating BKPyV-specific T-cell response, humoral response and overall T-cell phenotype beginning pre-transplant through one year post-transplant in 28 patients at two centers. We performed an exploratory analysis of risk factors for the development of viremia and viruria as well as compared the immune response to BKPyV in these groups and those who remained BK negative. 6 patients developed viruria and 3 developed viremia. BKPyV-specific CD8+ T-cells increased post-transplant in viremic and viruric but not BK negative patients. BKPyV-specific CD4+ T-cells increased in viremic, but not viruric or BK negative patients. Anti-BKPyV IgG antibodies increased in viruric and viremic patients but remained unchanged in BK negative patients. Viremic patients had a greater proportion of CD8+ effector cells pre-transplant and at 12 months post-transplant. Viremic patients had fewer CD4+ effector memory cells at 3 months post-transplant. Exploratory analysis demonstrated lower CD4 and higher total CD8 proportions, higher anti-BKPyV antibody titers and the cause of renal failure were associated BKPyV reactivation. In conclusion, low CD4, high CD8 and increased effector CD8 cells were found pre-transplant in patients who became viremic, a phenotype associated with immune senescence. This pre-transplant T-cell senescence phenotype could potentially be used to identify patients at increased risk of BKPyV reactivation.


Subject(s)
BK Virus/physiology , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Kidney Diseases/immunology , Kidney Transplantation , Virus Activation , Adult , Aged , Antibodies, Viral/biosynthesis , BK Virus/genetics , BK Virus/immunology , DNA, Viral/analysis , Female , Humans , Immunophenotyping , Kidney Diseases/surgery , Male , Middle Aged , Prospective Studies
4.
Clin Infect Dis ; 53(7): 711-5, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21852452

ABSTRACT

We examined whether prediagnostic John Cunningham virus (JCV) antibodies and viremia are predictors of progressive multifocal leukoencephalopathy (PML) in 83 PML cases and 240 human immunodeficiency virus (HIV) disease-matched controls. JCV viremia was not predictive of PML, but some patients showed higher anti-JCV immunoglobulin G (IgG) responses 6 months prior to diagnosis.


Subject(s)
Antibodies, Viral/blood , HIV Infections/complications , HIV-1/isolation & purification , JC Virus/isolation & purification , Leukoencephalopathy, Progressive Multifocal/diagnosis , Viremia , Adult , Female , HIV Infections/virology , Humans , Immunoglobulin G/blood , JC Virus/immunology , Male , Middle Aged , Predictive Value of Tests
5.
PLoS One ; 6(3): e16736, 2011 Mar 16.
Article in English | MEDLINE | ID: mdl-21436884

ABSTRACT

Conflicting prevalence of newly identified KI (KIPyV), WU (WUPyV) and Merkel Cell Carcinoma (MCPyV) polyomaviruses have been reported in progressive multifocal leukoencephalopathy (PML) patient samples, ranging from 0 to 14.3%. We analyzed the prevalence of these polyomaviruses in cerebrospinal fluid (CSF), peripheral blood mononuclear cells (PBMC), and bone marrow samples from PML patients, immunosuppressed individuals with or without HIV, and multiple sclerosis (MS) patients. Distinct PCR tests for KIPyV, WUPyV and MCPyV DNA performed in two independent laboratories detected low levels of MCPyV DNA only in 1/269 samples. The infrequent detections of these viruses in multiple samples from immunosuppressed individuals including those with PML suggest that their reactivation mechanisms may be different from that of JC polyomavirus (JCPyV) and that they do not play a role in the pathogenesis of PML.


Subject(s)
Immunosuppression Therapy , Leukoencephalopathy, Progressive Multifocal/virology , Polyomavirus/genetics , Humans , Immunocompetence , Leukoencephalopathy, Progressive Multifocal/diagnosis , Mass Screening
6.
J Virol ; 84(18): 9200-9, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20610709

ABSTRACT

JC virus (JCV) is latent in the kidneys and lymphoid organs of healthy individuals, and its reactivation in the context of immunosuppression may lead to progressive multifocal leukoencephalopathy (PML). Whether JCV is present in the brains or other organs of healthy people and in immunosuppressed patients without PML has been a matter of debate. We detected JCV large T DNA by quantitative PCR of archival brain samples of 9/24 (38%) HIV-positive PML patients, 5/18 (28%) HIV-positive individuals, and 5/19 (26%) HIV-negative individuals. In the same samples, we detected JCV regulatory region DNA by nested PCR in 6/19 (32%) HIV-positive PML patients, 2/11 (18%) HIV-positive individuals, and 3/17 (18%) HIV-negative individuals. In addition, JCV DNA was detected in some spleen, lymph node, bone, and kidney samples from the same groups. In situ hybridization data confirmed the presence of JCV DNA in the brains of patients without PML. However, JCV proteins (VP1 or T antigen) were detected mainly in the brains of 23/24 HIV-positive PML patients, in only a few kidney samples of HIV-positive patients, with or without PML, and rarely in the bones of HIV-positive patients with PML. JCV proteins were not detected in the spleen or lymph nodes in any study group. Furthermore, analysis of the JCV regulatory region sequences showed both rearranged and archetype forms in brain and extraneural organs in all three study groups. Regulatory regions contained increased variations of rearrangements correlating with immunosuppression. These results provide evidence of JCV latency in the brain prior to severe immunosuppression and suggest new paradigms in JCV latency, compartmentalization, and reactivation.


Subject(s)
Brain/virology , DNA, Viral/isolation & purification , JC Virus/isolation & purification , JC Virus/pathogenicity , Polyomavirus Infections/pathology , Polyomavirus Infections/virology , Virus Latency , Bone and Bones/virology , DNA, Viral/genetics , Gene Rearrangement , Humans , Kidney/virology , Lymph Nodes/virology , Polymerase Chain Reaction , Spleen/virology , Viral Proteins/analysis
8.
Lancet Neurol ; 9(4): 425-37, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20298966

ABSTRACT

Progressive multifocal leukoencephalopathy (PML) is a rare but often fatal brain disease caused by reactivation of the polyomavirus JC. Knowledge of the characteristics of PML has substantially expanded since the introduction of combination antiretroviral therapy during the HIV epidemic and the development of immune reconstitution inflammatory syndrome (IRIS) in patients with PML. Recently, the monoclonal antibodies natalizumab, efalizumab, and rituximab--used for the treatment of multiple sclerosis, psoriasis, haematological malignancies, Crohn's disease, and rheumatic diseases--have been associated with PML. Additionally, the JC virus can also lead to novel neurological disorders such as JC virus granule cell neuronopathy and JC virus encephalopathy, and might also cause meningitis. The increasingly diverse populations at risk and the recent discovery of the presence of the JC virus in the grey matter invite us to reappraise the pathogenesis of this virus in the CNS.


Subject(s)
JC Virus , Leukoencephalopathy, Progressive Multifocal/physiopathology , Polyomavirus Infections/physiopathology , Tumor Virus Infections/physiopathology , Humans , Leukoencephalopathy, Progressive Multifocal/diagnosis , Leukoencephalopathy, Progressive Multifocal/pathology , Leukoencephalopathy, Progressive Multifocal/therapy , Polyomavirus Infections/diagnosis , Polyomavirus Infections/pathology , Polyomavirus Infections/therapy , Tumor Virus Infections/diagnosis , Tumor Virus Infections/pathology , Tumor Virus Infections/therapy
9.
N Engl J Med ; 361(11): 1067-74, 2009 Sep 10.
Article in English | MEDLINE | ID: mdl-19741227

ABSTRACT

BACKGROUND: Progressive multifocal leukoencephalopathy (PML) occurs in a fraction of patients with multiple sclerosis who were treated with natalizumab. Most adults who are infected with the JC virus, the etiologic agent in PML, do not have symptoms. We sought to determine whether exposure to natalizumab causes subclinical reactivation and neurotropic transformation of JC virus. METHODS: We followed 19 consecutive patients with multiple sclerosis who were treated with natalizumab over an 18-month period, performing quantitative polymerase-chain-reaction assays in blood and urine for JC virus reactivation; BK virus, a JC virus-related polyomavirus, was used as a control. We determined JC virus-specific T-cell responses by means of an enzyme-linked immunospot assay and antibody responses by means of an enzyme-linked immunosorbent assay and analyzed JC virus regulatory-region sequences. RESULTS: After 12 months of natalizumab therapy, the prevalence of JC virus in the urine of the 19 patients increased from a baseline value of 19% to 63% (P=0.02). After 18 months of treatment, JC virus was detectable in 3 of 15 available plasma samples (20%) and in 9 of 15 available samples of peripheral-blood mononuclear cells (60%) (P=0.02). JC virus regulatory-region sequences in blood samples and in most of the urine samples were similar to those usually found in PML. Conversely, BK virus remained stable in urine and was undetectable in blood. The JC virus-specific cellular immune response dropped significantly between 6 and 12 months of treatment, and variations in the cellular immune response over time tended to be greater in patients in whom JC viremia developed. None of the patients had clinical or radiologic signs of PML. CONCLUSIONS: Subclinical reactivation of JC virus occurs frequently in natalizumab-treated patients with multiple sclerosis. Viral shedding is associated with a transient drop in the JC virus-specific cellular immune response.


Subject(s)
Antibodies, Monoclonal/adverse effects , Integrin alpha4/immunology , JC Virus/physiology , Leukoencephalopathy, Progressive Multifocal/chemically induced , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Virus Activation/drug effects , Adult , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antibodies, Viral/blood , DNA, Viral/blood , Female , Humans , JC Virus/genetics , JC Virus/immunology , JC Virus/isolation & purification , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/complications , Natalizumab , Pilot Projects , Urine/virology , Viral Load , Viremia/diagnosis , Young Adult
10.
J Infect Dis ; 199(6): 881-8, 2009 Mar 15.
Article in English | MEDLINE | ID: mdl-19434914

ABSTRACT

BACKGROUND: We sought to determine the prevalence of JC virus (JCV) in bone marrow samples from human immunodeficiency virus (HIV)-positive and HIV-negative patients and to determine whether bone marrow is a site of latency and neurotropic transformation of JCV, the agent of progressive multifocal leukoencephalopathy (PML). METHODS: We collected bone marrow aspirates, archival bone marrow samples, and blood and urine samples from 75 HIV-negative and 47 HIV-positive patients without PML as well as bone marrow and urine or kidney samples from 8 HIV-negative and 15 HIV-positive patients with PML. Samples were tested for JCV DNA by quantitative polymerase chain reaction and for JCV protein expression by immunohistochemical analysis. JCV regulatory regions (RRs) were characterized by sequencing. RESULTS: JCV DNA was detected in bone marrow samples from 10 (13%) of 75 and 22 (47%) of 47 of the HIV-negative and HIV-positive patients without PML, respectively, compared with 3 (38%) of 8 and 4 (27%) of 15 of the HIV-negative and HIV-positive patients with PML. JCV DNA (range, 2-1081 copies/microg of cellular DNA) was detected in multiple leukocyte subpopulations of blood and bone marrow samples. JCV large T antigen, but not VP1 capsid protein, was expressed in bone marrow plasma cells. Bone marrow JCV RR sequences were similar to those usually found in the brains of patients with PML. CONCLUSIONS: Bone marrow is an important reservoir and a possible site of neurotropic transformation for JCV.


Subject(s)
Bone Marrow/virology , DNA, Viral/analysis , HIV Seronegativity , HIV Seropositivity/virology , JC Virus/isolation & purification , Viral Proteins/analysis , Virus Latency , Antigens, CD/analysis , Blood/virology , Bone Marrow/immunology , HIV Seropositivity/blood , HIV Seropositivity/urine , Humans , Immunohistochemistry , JC Virus/genetics , JC Virus/physiology , Urine/virology
11.
J Neurovirol ; 14(5): 455-8, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18989816

ABSTRACT

The polyomavirus JC (JCV) is the etiologic agent of progressive multifocal leukoencephalopathy (PML). JCV remains quiescent in kidneys, where it displays a stable archetypal regulatory region (RR). Conversely, rearranged JCV RR, including tandem repeat patterns found in the central nervous system (CNS) of PML patients, have been associated with neurovirulence. The precise site and mechanism of JCV RR transformation is unknown. We present herein a patient with rheumatoid arthritis treated with methotrexate, who developed PML and had a rapid fatal outcome. JCV DNA polymerase chain reaction (PCR) was positive in cerebrospinal fluid (CSF), bone marrow, blood, and urine. Double-immunohistochemical staining demonstrated that 9% of bone marrow CD138(+) plasma cells sustained productive infection by JCV, accounting for 94% of JCV-infected cells. JCV RR analysis revealed archetype and rearranged RR forms in bone marrow, whereas RR with tandem repeat was predominant in blood. These results suggest that the bone marrow may be a potential site of JCV pathogenic transformation. Further studies will be needed to determine the prevalence of JCV in bone marrow of immunosuppressed individuals at risk of PML and characterize the RR and phenotype of these JCV isolates.


Subject(s)
Bone Marrow/virology , DNA, Viral/cerebrospinal fluid , JC Virus/isolation & purification , Leukoencephalopathy, Progressive Multifocal/physiopathology , Regulatory Sequences, Nucleic Acid/genetics , Aged , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/genetics , Brain/virology , Cerebrospinal Fluid/virology , DNA, Viral/analysis , DNA, Viral/blood , DNA, Viral/genetics , Gene Rearrangement , Humans , JC Virus/genetics , Leukoencephalopathy, Progressive Multifocal/genetics , Leukoencephalopathy, Progressive Multifocal/virology , Magnetic Resonance Imaging , Male , Molecular Sequence Data , Tandem Repeat Sequences/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...